Loading...
•
Sep 30, 2025
LifeStance Q3 2025 Earnings Report
Estimated Revenue:$359M
+14.5% YoY
Estimated EPS:$0.02
+127.9% YoY
Key Takeaways
LifeStance generated third quarter 2025 revenue of 356800000, representing solid year-over-year growth driven by higher visit volumes and clinician expansion. Net income was 6200000 and Adjusted EBITDA reached 42000000, reflecting continued operating leverage and margin improvement.
Revenue increased year-over-year to 356800000 driven by volume growth.
Visit volumes grew to 2300000 supported by clinician expansion.
Net income improved to 6200000 compared to prior-year loss.
Adjusted EBITDA increased to 42000000 reflecting operating leverage.
Forward Guidance
The company reaffirmed full year 2025 guidance, expecting continued revenue growth, Center Margin expansion, and Adjusted EBITDA improvement supported by clinician productivity and visit growth.
Positive Outlook
- Sustained double-digit revenue growth.
- Continued clinician base expansion.
- Improving operating leverage.
- Rising Center Margin year-over-year.
- Strong Adjusted EBITDA growth trajectory.
Challenges Ahead
- Exposure to reimbursement rate pressures.
- Dependence on clinician recruitment and retention.
- Ongoing interest expense impact.
- Regulatory and healthcare compliance risks.
- Macroeconomic factors could affect patient demand.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...